- Vincerx Pharma Inc (NASDAQ:VINC) presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
- High expression of CXCR5 was observed by immunohistochemistry on naive and previously treated diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) samples; with limited expression in healthy tissues.
- VIP924 showed superior in vitro cytotoxicity across different non-Hodgkin lymphoma cell lines compared with other B-cell lymphoma targeting antibodies conjugated to the same effector chemistry.
- VIP924 (10mg/kg) resulted in significant tumor growth inhibition in two DLBCL patient-derived tumor models: 68% in a low CXCR5-expressing model and 87% in a high CXCR5-expressing model.
- Prolonged survival of VIP924-treated animals was observed in both models. No effect on body weight or adverse effects in the VIP924-treated mice were observed.
- To determine the efficacy of VIP924 in large, established tumors, a single VIP924 dose of 10mg/kg was administered in mice transplanted with the HBL-1 lymphoma cell line.
- Complete responses were observed in 2 out of 3 mice with no measurable tumors on treatment day 26.
- After 24 and 48 hours, accumulation of VIP716 (ie, payload; “metabolite”) was observed in the tumors but not in plasma.
- Price Action: VINC shares are down 4.21% at $0.98 on the last check Wednesday.
Why Microchip Technology Shares Are Diving Today
Microchip Technology Inc (NASDAQ: MCHP) shares are trading lower by around 6% after the company reported
